Fungal Biofilms and Drug Resistance

Emerging Infectious Diseases

Volumn 10, Issue 1, 2004, Pages 14-19

  Jabra Rizk, Mary Ann ^a   Falkler, William A ^a   Meiller, Timothy F ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ANTIFUNGAL AGENT; ECHINOCANDIN B DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA; CATHETER INFECTION; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; HUMAN; INTRAVASCULAR CATHETER; MYCOSIS; NONHUMAN;

EID: 0347991888     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid1001.030119     Document Type: Article

References (40)

1. Calderone RA, editor. Candida and candidiasis. Washington: ASM Press; 2002.
2. Douglas LJ. Medical importance of biofilms in Candida infections. Rev Iberoam Micol 2002;19:139-43.
3. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol 2003;11:30-6.
4. Baillie GS, Doublas LJ. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J Antimicrob Chemother 2000;46:397-403.
5. Chandra J, Kuhn DM, Mulherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001;183:5385-94.
6. Ellis M. Invasive fungal infections: evolving challenges for diagnosis and therapeutics. Mol Immunol 2002;38:947-57.
7. O'Toole GA, Kaplan HB, Kolter R. Biofilm formation as microbial development. Annu Rev Microbiol 2000;54:49-79.
8. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL. Biofilm formation by Candida dubliniensis. J Clin Microbiol 2001;39:3234-40.
9. Ramage G, Bachmann S, Patterson TF, Wickes BL, Lopez-Ribot JL. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002;49:973-80.
10. Sullivan D, Coleman D. Candida dubliniensis: an emerging opportunistic pathogen. Curr Top Med Mycol 1997;8:15-25.
11. Pfaller MA, Messer SA, Gee S, Joly S, Pujol C, Sullivan DJ, et al. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol 1999;37:870-2.
12. Moran GP, Sanglard D, Donnelly SM, Shanley D, Sullivan DJ, Coleman DC. Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrobial Agents Chemother 1998;42:1819-30.
13. Jabra-Rizk MA, Falkler WA Jr, Merz WG, Baqui AAMA, Kelley JI, Meiller TF. Retrospective identification of Candida dubliniensis among Candida albicans clinical laboratory isolates from HIV and non-HIV individuals. J Clin Microbiol 2000;38:2423-6.
14. Adam B, Baillie GS, Douglas LJ. Mixed species biofilms of Candida albicans and Staphylococcus epidermidis. J Med Microbiol 2002;51:344-9.
15. Donlan RM. Biofilms: microbial life on surfaces. Emerg Infect Dis 2002;8:1-19.
16. Lewis K. Riddle of biofilm resistance. Antimicrobial Agents Chemother 2001;45:999-1007.
17. Davey ME, O'Toole GA. Microbial biofilms: from ecology to molecular genetics. Microbiol Mol Biol Rev 2000;64:847-67.
18. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002;15:167-93.
19. Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, et al. In vitro activity of caspofungin against Candida albicans biofilm. Antimicrobial Agents Chemother 2002;46:3591-6.
20. Jabra-Rizk MA, Falkler WA Jr, Merz WG, Kelley JI, Baqui AAMA, Meiller TF. Coaggregation of Candida dubliniensis with Fusobacterium nucleatum. J Clin Microbiol 1999;37:1464-8.
21. Jabra-Rizk MA, Falkler WA Jr, Merz WG, Kelley JI, Baqui AAMA, Meiller TF. Candida dubliniensis and Candida albicans display surface variations consistent with observed intergeneric coaggregation. Rev Iberoam Micol 1999;16:8-14.
22. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrobial Agents Chemother 2001;45:2475-9.
23. Martinez M, Lopez-Ribot JL, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF. Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J Clin Microbiol 2002;40:3135-9.
24. Quindos G, Carrillo-Munoz AJ, Arevalo MP, Salgado J, Alonso-Vargas R, Rodrigo JM, et al. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy 2000;46:395-401.
25. Wynn RL, Jabra-Rizk MA, Meiller TF. Antifungal drugs and fungal resistance: the need for a new generation of drugs. Gen Dent 1999;47:352-5.
26. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrobial Agents Chemother 2002;46:1704-13.
27. Harry JB, Song JL, Lyons CN, White TC. Transcription initiation of genes associated with azole resistance in Candida albicans. Med Mycol 2002;40:73-81.
28. Wirsching S, Moran GP, Sullivan DJ, Coleman DC, Morschhauser J. MDR1-mediated drug resistance in Candida dubliniensis. Antimicrobial Agents Chemother 2001;45:3416-21.
29. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrobial Agents Chemother 2002;46:1773-80.
30. Andriole VT. Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother 1999;44:151-61.
31. Wynn RL, Jabra-Rizk MA, Meiller TF. Fungal drug resistance, biofilms, and new antifungals. Gen Dent 2003;51:94-8.
32. Arathoon EG. Clinical efficacy of echinocandin antifungals. Curr Opin Infect Dis 2001;14:685-91.
33. Cuenca-Estrella M, Mellado E, Diaz-Guerra TM, Monzon A, Rodriguez-Tudela JL. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, intraconazole and amphotericin B. J Antimicrob Chemother 2000;46:475-7.
34. Denning DW. Echinocandins: a new class of antifungal. J Antimicrob Chemother 2002;49:889-91.
35. Graybill JR. The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Int J Clin Pract 2001;55:633-8.
36. Groll AH, Walsh TJ. Antifungal chemotherapy: advances and perspectives. Swiss Med Wkly 2002;132:303-11.
37. Georgopapadakou NH. Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors. Expert Opin Investig Drugs 2001;10:269-80.
38. Mora-Duarte J, Betts R, Rotstein C. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9.
39. Roling EE, Klepser ME, Wasson A, Lewis RE, Ernst EJ, Pfaller MA. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis 2002;43:13-7.
40. Walsh TJ. Echinocandins - an advance in the primary treatment of invasive candidiasis. N Engl J Med 2002;347:2070-2.